SciCombinator

Discover the most talked about and latest scientific content & concepts.

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

OPEN Annals of oncology : official journal of the European Society for Medical Oncology / ESMO | 26 Feb 2015

CY Cheah, D Chihara, JE Romaguera, NH Fowler, JF Seymour, FB Hagemeister, RE Champlin and ML Wang
Abstract
Although ibrutinib is highly effective in patients with relapsed/refractory mantle cell lymphoma (MCL), a substantial proportion of patients have resistant disease. The subsequent outcomes of such patients are unknown.
Tweets*
15
Facebook likes*
0
Reddit*
0
News coverage*
1
Blogs*
0
SC clicks
4
Concepts
Mantle zone, Lymphoma, Chemotherapy, Cancer, Mantle cell lymphoma
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com